Analysts expect Telix Pharmaceuticals Ltd to report revenue of 958.31 M for 2026, against a range of 893.90 M to 1.02 B. The most recent reported year, 2025, came in at 803.80 M, a 4.4% miss against the 840.74 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 5.39 M | 107.96 M | 329.70 M | 499.29 M | 803.80 M | - | - | ||
| High Estimate | 6.10 M | 107.83 M | 350.02 M | 501.96 M | 899.01 M | 1.02 B | 1.39 B | ||
| Low Estimate | 5.57 M | 97.42 M | 307.62 M | 412.55 M | 782.48 M | 893.90 M | 1.26 B | ||
| Consensus Estimate | 5.84 M | 102.62 M | 328.82 M | 457.25 M | 840.74 M | 958.31 M | 1.32 B |
Analysts expect Telix Pharmaceuticals Ltd to report earnings per share of 0.08 for 2026, against a range of 0.08 to 0.08. The most recent reported year, 2025, came in at -0.02, a 300.0% miss against the 0.01 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.20 | -0.19 | 0.08 | 0.09 | -0.02 | - | - | ||
| High Estimate | -0.11 | -0.16 | 0.07 | 0.15 | 0.01 | 0.08 | 0.06 | ||
| Low Estimate | -0.13 | -0.20 | 0.05 | 0.13 | 0.01 | 0.08 | 0.06 | ||
| Consensus Estimate | -0.12 | -0.18 | 0.06 | 0.14 | 0.01 | 0.08 | 0.06 |
Pull Wall Street consensus for Telix Pharmaceuticals Ltd (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=TLX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "TLX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=TLX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();